Uros Velickovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Uros Velickovic has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Dragan Milovanovic
Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
2 shared publications - Dragica Selakovic
Department of Physiology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
2 shared publications - Gvozden Rosic
Department of Physiology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
2 shared publications - Marina Mitrovic
Department of Medical Biochemistry, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
2 shared publications - Nemanja Jovicic
Department of Histology and Embryology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
2 shared publications - Sara Rosic
Department of Physiology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
2 shared publications
Latest Publications
- Open Access
- 10 September 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (9) , 2216
Correction: Velickovic et al. The Advances in Antipsychotics-Induced Dyskinesia Rodent Models: Benefits of Antioxidant Supplementation. Biomedicines 2025, 13, 512
The authors would like to make the following corrections to this published paper
- 10 September 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (9) , 2216
Open AccessCorrection: Velickovic et al. The Advances in Antipsychotics-Induced Dyskinesia Rodent Models: Benefits of Antioxidant Supplementation. Biomedicines 2025, 13, 512
The authors would like to make the following corrections to this published paper
- Open Access
- 18 February 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (2) , 512
The Advances in Antipsychotics-Induced Dyskinesia Rodent Models: Benefits of Antioxidant Supplementation
After 70 years of clinical practice with antipsychotics in the treatment of some specific serious mental disorders, much information has been accumulated considering their efficiency as a first-line evidence-based schizophrenia therapy, but also on their adverse effects within the range from minor to life-threatening issues. In this paper, we highlight motor impairment as a frequent limiting factor. Despite the diversity of side effects following antipsychotics usage, many of those who suffer share the same pathophysiological background issues, such as oxidative damage, neuroinflammation, apoptosis, and neurodegeneration (observed in the brain regions involved in motor control). The obvious need to solve these limitations is facing restraints in clinical studies due to the ethical issues. Therefore, it seems reasonable to address the importance of preclinical investigations to overcome the adverse effects of antipsychotics. For that purpose, we analyzed the antipsychotics-induced dyskinesia seen in rodent models, with a special focus on attempts to highlight the benefits of antioxidant supplementation. Our analysis has revealed that antioxidant supplementation, with various antioxidant-rich compounds, confirms the clear neuroprotective effects of the therapy of this iatrogenic dyskinesia. Given their accessibility and safety, it seems that the administration of antioxidant-rich compounds in various forms, as an adjuvant therapy, may be beneficial in patients by lowering the risk of secondary Parkinsonism. Also, it seems that the strategy for further investigations in this field of preclinical studies should be standardized and should include more antipsychotics employed in the clinical practice.
- 18 February 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (2) , 512
Open AccessThe Advances in Antipsychotics-Induced Dyskinesia Rodent Models: Benefits of Antioxidant Supplementation
After 70 years of clinical practice with antipsychotics in the treatment of some specific serious mental disorders, much information has been accumulated considering their efficiency as a first-line evidence-based schizophrenia therapy, but also on their adverse effects within the range from minor to life-threatening issues. In this paper, we highlight motor impairment as a frequent limiting factor. Despite the diversity of side effects following antipsychotics usage, many of those who suffer share the same pathophysiological background issues, such as oxidative damage, neuroinflammation, apoptosis, and neurodegeneration (observed in the brain regions involved in motor control). The obvious need to solve these limitations is facing restraints in clinical studies due to the ethical issues. Therefore, it seems reasonable to address the importance of preclinical investigations to overcome the adverse effects of antipsychotics. For that purpose, we analyzed the antipsychotics-induced dyskinesia seen in rodent models, with a special focus on attempts to highlight the benefits of antioxidant supplementation. Our analysis has revealed that antioxidant supplementation, with various antioxidant-rich compounds, confirms the clear neuroprotective effects of the therapy of this iatrogenic dyskinesia. Given their accessibility and safety, it seems that the administration of antioxidant-rich compounds in various forms, as an adjuvant therapy, may be beneficial in patients by lowering the risk of secondary Parkinsonism. Also, it seems that the strategy for further investigations in this field of preclinical studies should be standardized and should include more antipsychotics employed in the clinical practice.